
OmniAb Inc (OABI) Stock Forecast & Price Target
OmniAb Inc (OABI) Analyst Ratings
Bulls say
OmniAb Inc demonstrated strong financial performance in 1Q25, reporting revenues of $4.2 million, which reflects a 9% increase year-over-year, highlighting the company's ability to grow amid a competitive landscape. The company also showed progress in reducing net losses to $18.2 million, or ($0.17) per share, compared to a loss of $19.0 million, or ($0.19) per share in the prior year, indicating improved operational efficiency. With a solid balance sheet and anticipated catalysts in both near- and long-term R&D efforts, OmniAb is well-positioned for upward momentum in its stock performance.
Bears say
OmniAb Inc. has experienced a decline in stock value post-merger with Avista Public Acquisition Corporation II, which mirrors adverse market trends impacting similar biotechnology transactions and established firms. The company's projected operating cash burn for the current year is expected to be below that of 2024, indicating potential concerns regarding financial sustainability and management of expenditures. These financial dynamics raise questions about the company's short-term viability and ability to maintain investor confidence in a challenging market environment.
This aggregate rating is based on analysts' research of OmniAb Inc and is not a guaranteed prediction by Public.com or investment advice.
OmniAb Inc (OABI) Analyst Forecast & Price Prediction
Start investing in OmniAb Inc (OABI)
Order type
Buy in
Order amount
Est. shares
0 shares